#prostatecancer #management - surveillance for everyone?! https://t.co/C06e5LUsG1 @NEJM
ProtecT trial: no survival advantage in AS vs therapy in prospective trial. Included > 20% of men with GS 7+ dz. https://t.co/lFomakZWL7
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — NEJM https://t.co/QGOK7nGMX0
RT @CoyneoftheRealm: 10-Year Outcomes for Surgery, Radiotherapy for Localized Prostate Cancer no Better than Watchful Waiting @NEJM https:…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — NEJM https://t.co/bdIMMFf1sL
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — https://t.co/qnChIxEYK5 https://t.co/VqcvJj6xi9
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
10-Year Outcomes for Surgery, Radiotherapy for Localized Prostate Cancer no Better than Watchful Waiting @NEJM https://t.co/aAk0miHKyU
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
10-Year outcomes NEJM comparative effectiveness of prostate cancer treatments detected by PSA remains uncertain https://t.co/PX7RGhiXU0
"Deaths from any cause were evenly distributed across the treatment groups..." https://t.co/7nwN3isHwv
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — NEJM $MDVN $PFE https://t.co/qr0USK3R0k
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
RT @NEJM: Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nC…
Original Article: Mortality and Clinical Outcomes in the ProtecT Trial https://t.co/nlI4wTKhlu #prostatecancer https://t.co/NH2nCjPs1E
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
17/1643 PCa deaths @10yr: low-risk prostate cancer is unlikely to kill (~1%) whatever strategy #ProtecT https://t.co/KTzjYHzJ8f via @NEJM
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
RT @LoebStacy: Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://…
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — NEJM https://t.co/ylFZ5keAVB
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — NEJM https://t.co/cBXYv9EYH4
Hot off the press: ProtecT randomized trial surgery vs radiation vs active monitoring for #prostatecancer in @NEJM https://t.co/w7DDtY3GAG